期刊文献+

卡托普利片联合珍菊降压片治疗老年患者原发性高血压的临床疗效观察 被引量:14

Clinical observation of Captopril Tablet combined with Zhenju Hypotensive Tablet in treatment of primary hypertension in gerontal patients
原文传递
导出
摘要 目的研究卡托普利片联合珍菊降压片对原发性老年高血压患者的临床疗效。方法将上海市虹口区江湾镇街道社区卫生服务中心诊疗的68例原发性高血压患者随机分为治疗组(34例)和对照组(34例),对照组口服卡托普利片12.5 mg/次,3次/d,疗程4周;治疗组口服卡托普利片,每次12.5 mg,3次/d,同时口服珍菊降压片,0.48 g/次,3次/d,均于每天早餐前服用,4周为1疗程。治疗前后测量患者血压进行疗效分析,同时严密观察患者的不良反应。结果治疗后,两组患者的收缩压和舒张压均有明显改变,且与治疗前相比差异均有统计学意义(P<0.05)。治疗组和对照组收缩压下降幅度分别为14.3%、8.4%,两组比较差异有统计学意义(P<0.05);舒张压下降幅度分别为22.7%、19.3%,两组比较差异有统计学意义(P<0.05)。治疗组和对照组总有效率分别为97.1%、85.3%,两组比较差异有统计学意义(P<0.05)。两组患者均未见严重不良反应。结论卡托普利片联合珍菊降压片治疗老年原发性高血压的临床疗效较好,且不良反应少,值得在社区推广应用。 Objective To observe the efficacy of Captopril Tablets combined with Zhenju Hypotensive Tablets(CT-ZHT) in the treatment of primary hypertension in gerontal patients of Jiangwan Community Health Center of Hongkou District of Shanghai. Methods The elderly patients(68 cases) with primary hypertension were randomly divided into the treatment(34 cases) and control(34 cases) groups. The patients in the control group were given CT 12.5 mg for three times every day during four weeks and the patients in the treatment group were given CT 12.5 mg and ZHT 0.48 g for three times every day for four weeks. Blood pressure was measured before and after treatment.. All the participants were closely observed and recored of any adverse reactions. Results After treatment, the blood pressure was significantly lower than before treatment with significant difference(P〈0.05). At the end of week 4,The systolic blood pressure of treatment and control groups decreased by 14.3% and 8.4% respectively, with statistically significant difference(P〈0.05); Diastolic blood pressure decreased by 22.7% and 19.3% respectively, with statistically significant difference(P〈0.05). The antihypertensive effective rates in the treatment and control groups were 97.1% and 85.3%, respectively. There were obvious differences in the effects of both hypotensive drugs(P0.05). Blood routine examination, routine urine test, blood lipids, blood glucose, liver and kidney function showed no abnormality. Few adverse reactions were observed in both groups and the difference was no remarkable statistically. Conclusion CT-ZHT in the treatment of primary hypertension has good antihypertensive effect in elderly patients with primary hypertension, producing few side effects and well patient compliance.
作者 王菲
出处 《现代药物与临床》 CAS 2014年第3期278-281,共4页 Drugs & Clinic
关键词 卡托普利片 珍菊降压片 高血压 临床疗效 Captopril Tablet Zhenju Hypotensive Tablet hypertension clinical curative effect
  • 相关文献

参考文献14

  • 1Chobanian A V, Bakris G L, Black H R, et al. The Seventh report of the Joint National Committee on rrevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report [J]. JAMA, 2003, 289 (19): 2560-2572. 被引量:1
  • 2Pepine C J, Handberg E M, Cooper-DeHoff R M, et al.Acalcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): arandomized controlled trial [J]. JAMA, 2003, 290(21): 2805-2816. 被引量:1
  • 3Hansson L, Zanchetti A, Carruthers S G, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patibnts with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial [J]. Lancet, 1998, 351(9118): 1755-1762. 被引量:1
  • 4刘国仗,马文君,王兵.高血压药物治疗的现状和展望[J].中华心血管病杂志,2003,31(2):157-158. 被引量:121
  • 5吕卓人,梁磊,艾文婷.血管紧张素Ⅱ1型受体拮抗剂研究进展[J].中华心血管病杂志,2004,32(11):1054-1056. 被引量:61
  • 6中国高血压防治指南[J].高血压杂志,2000,8(2):103-112. 被引量:172
  • 7WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization-International society of hypertension guidelines for the management of hypertension [J]. J Hypertens, 1999, 17(2): 151-183. 被引量:1
  • 8金香兰,张允岭,孟繁兴,张綦慧,郭蓉娟,陈志刚,张志晨,郑硕,牛焕敏,邹敬韬,王乐,白文,曹晓岚,张玉莲,赵建军,陈志强,常富业.高血压病低危组证候要素初探[J].中华中医药杂志,2011,26(1):36-39. 被引量:10
  • 9王佐广,温绍君,陈光慧,张维君,文杰,刘雅,刘洁琳,汤健.高血压相关基因1基因突变与原发性高血压发生的关系[J].中国临床康复,2005,9(3):84-86. 被引量:2
  • 10Aiexander M, Tekana I, Hunkeler E, et al. Evaluating hypertension control in a managed caresetting [J]. Arch lntMed, 1999, 159: 2673-2677. 被引量:1

二级参考文献55

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2吴文静,柯元南,孙宁玲,余振球,杨新春,秦延莉,姜红.缬沙坦与氢氯噻嗪复方制剂治疗轻中度原发性高血压临床疗效观察[J].中日友好医院学报,2006,20(6):323-326. 被引量:17
  • 3邹志东,范晔,周小棠,陈玉娇,李凤婷,张超.1996~2005年北京地区高血压病中医证候分析[J].中医杂志,2007,48(5):437-439. 被引量:30
  • 4Chen KH, Guo X, Ma D, et al.Dysregulation of HSG triggers vascular proliferative disorders.Nat Cell Biol 2004; 6 (9): 872- 83. 被引量:1
  • 5Hao K,Xu X, Laird N,et al.Power estimation of multiple SNP association test of case-control study and application.Genet Epidemiol 2004;26(1):22- 30. 被引量:1
  • 6Santel A,Fuller MT.Control of mitochondrial morphology by a human mitofusin.J Cell Sci 2001;114 (Pt 5): 867- 74. 被引量:1
  • 7Pitt B,Segal R.Martinez FA,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).Lancet, 1997,349:747-752. 被引量:1
  • 8Pitt B,Poole-Wilson PA,Segal R,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.Lancet, 2000,355:1582-1587. 被引量:1
  • 9Daholof B,Devereux RB,Kjeldsen SE,et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet,2002,359:995-1003. 被引量:1
  • 10Lewis EJ,Hunsicker LG,Clarke WR,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med, 2001,345:851-860. 被引量:1

共引文献384

同被引文献127

引证文献14

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部